Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia

Carly Oboudiyat*, Tamar Gefen, Eleni Varelas, Sandra Weintraub, Emily Rogalski, Eileen H. Bigio, M. Marsel Mesulam

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Introduction The accuracy of cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer's disease (AD) pathology has not been fully validated in autopsied nonamnestic dementias. Methods We retrospectively evaluated CSF amyloid β 1–42, phosphorylated-tau, and amyloid-tau index as predictors of Alzheimer pathology in patients with primary progressive aphasia, frontotemporal dementia, and progressive supranuclear palsy. Results Nineteen nonamnestic autopsied cases with relevant CSF values were included. At autopsy, nine had AD and 10 had non-AD pathologies. All six patients whose combined CSF phosphorylated-tau and amyloid β levels were “consistent with AD” had postmortem Alzheimer pathology. The two patients whose biomarker values were “not consistent with AD” had non-AD pathologies. The CSF values of the remaining eight non-AD cases were in conflicting or borderline ranges. Discussion CSF biomarkers reliably identified Alzheimer pathology in nonamnestic dementias and may be useful as a screening measure for inclusion of nonamnestic cases into Alzheimer's trials.

Original languageEnglish (US)
Pages (from-to)598-601
Number of pages4
JournalAlzheimer's and Dementia
Volume13
Issue number5
DOIs
StatePublished - May 2017

    Fingerprint

Keywords

  • Atypical Alzheimer's disease
  • Behavioral variant frontotemporal dementia
  • Neuropathology
  • Primary progressive aphasia
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this